Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Praxis Precision Medicines's current 3-Year Share Buyback Ratio was -97.10%.
The historical rank and industry rank for Praxis Precision Medicines's 3-Year Share Buyback Ratio or its related term are showing as below:
PRAX'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -97.1 Med: -51.1 Max: -7.2
Current: -97.1
During the past 8 years, Praxis Precision Medicines's highest 3-Year Share Buyback Ratio was -7.20%. The lowest was -97.10%. And the median was -51.10%.
PRAX's 3-Year Share Buyback Ratio is ranked worse than 91% of 1189
companies
in the Biotechnology industry
Industry Median: -11.8
vs PRAX: -97.10
Praxis Precision Medicines (NAS:PRAX) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Praxis Precision Medicines 3-Year Share Buyback Ratio Related Terms
PRAX vs KYMR, PTGX, CYTK: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Praxis Precision Medicines's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Praxis Precision Medicines 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Praxis Precision Medicines's 3-Year Share Buyback Ratio falls into.
Praxis Precision Medicines 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -97.10 mean?
Praxis Precision Medicines (PRAX) has a 3-Year Share Buyback Ratio of -97.10 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Praxis Precision Medicines and its competitors. According to the industry distribution chart, Praxis Precision Medicines ranks #1082 out of 1189 companies in the Biotechnology industry, placing it in the top 91%.
Is Praxis Precision Medicines' 3-Year Share Buyback Ratio too high?
Praxis Precision Medicines' current 3-Year Share Buyback Ratio is -97.10. Based on the distribution chart, Praxis Precision Medicines ranks #1082 out of 1189 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Praxis Precision Medicines has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Praxis Precision Medicines' 3-Year Share Buyback Ratio compare to KYMR and PTGX?
According to the Biotechnology industry distribution chart, Praxis Precision Medicines ranks #1082 out of 1189 companies for 3-Year Share Buyback Ratio. This places Praxis Precision Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Praxis Precision Medicines and its competitors. Praxis Precision Medicines's current 3-Year Share Buyback Ratio is -97.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praxis Precision Medicines stock overvalued right now?
Based on GuruFocus' analysis, Praxis Precision Medicines (PRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $15.78, compared to a current price of $357.50 — trading 2165.5% above its estimated fair value. The current 3-Year Share Buyback Ratio is -97.10. Praxis Precision Medicines' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Praxis Precision Medicines (PRAX), the current 3-Year Share Buyback Ratio is -97.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Praxis Precision Medicines (PRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued.
The current stock price of $357.50 is trading 2165.5% above its estimated GF Value™ of $15.78.
GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.
Key valuation signals for PRAX:
3-Year Share Buyback Ratio: -97.10
GF Value™: $15.78 vs. price of $357.50 (2165.5% above fair value)
No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score
Get the complete analysis for PRAX
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRAX has been successfully added to your 
